Advertisement
UK markets close in 3 hours 56 minutes

  • FTSE 100

    8,297.55
    +84.06 (+1.02%)
     

  • FTSE 250

    20,402.35
    +237.81 (+1.18%)
     

  • AIM

    777.45
    +5.92 (+0.77%)
     

  • GBP/EUR

    1.1647
    -0.0013 (-0.11%)
     

  • GBP/USD

    1.2547
    -0.0017 (-0.14%)
     

  • Bitcoin GBP

    51,017.41
    -229.45 (-0.45%)
     

  • CMC Crypto 200

    1,328.76
    -36.37 (-2.66%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.15
    -0.33 (-0.42%)
     

  • GOLD FUTURES

    2,323.80
    -7.40 (-0.32%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,292.08
    +116.87 (+0.64%)
     

  • CAC 40

    8,026.76
    +30.12 (+0.38%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session

Zacks Equity Research
Updated

Pieris Pharmaceuticals, Inc. PIRS was a big mover last session, as the company saw its shares rise more than 15% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $5.64 to $6.37 in the past one-month time frame.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Pieris Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Pieris Pharmaceuticals, Inc. Price

Pieris Pharmaceuticals, Inc. Price | Pieris Pharmaceuticals, Inc. Quote

ADVERTISEMENT

Investors interested in the Medical - Biomedical and Genetics industry may consider Protagonist Therapeutics, Inc. PTGX, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is PIRS going up? Or down? Predict to see what others think:Up or Down

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Protagonist Therapeutics, Inc. (PTGX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research